Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.54 |
| ▸ | NPC1 | O15118 | 6/20 | 0.54 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL871515 | 1.00 | RAB9A (0.54) | RAB9ANPC1TNKSKDM4ESMN1; SMN2 | |
| SCHEMBL871133 | 0.93 | NPC1 (0.49) | RAB9ANPC1TNKSKDM4ESMN1; SMN2 | |
| SCHEMBL871132 | 0.93 | NPC1 (0.49) | RAB9ANPC1TNKSKDM4ESMN1; SMN2 | |
| SCHEMBL3016765 | 0.92 | NPC1 (0.44) | RAB9ANPC1TNKSKDM4ESMN1; SMN2 | |
| SCHEMBL4224554 | 0.91 | NPC1 (0.46) | RAB9ANPC1TNKSKDM4ESMN1; SMN2 | |
| SCHEMBL4224541 | 0.91 | NPC1 (0.46) | RAB9ANPC1TNKSKDM4ESMN1; SMN2 | |
| SCHEMBL871786 | 0.90 | NPC1 (0.46) | RAB9ANPC1TNKSKDM4ESMN1; SMN2 | |
| SCHEMBL872858 | 0.90 | NPC1 (0.46) | RAB9ANPC1TNKSKDM4ESMN1; SMN2 | |
| SCHEMBL870643 | 0.90 | NPC1 (0.44) | RAB9ANPC1TNKSKDM4ESMN1; SMN2 | |
| SCHEMBL870644 | 0.90 | NPC1 (0.44) | RAB9ANPC1TNKSKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2106396-B1 | CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | ALCON RES LTD (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20120077801-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2012-03-29 | — | — | US | disclosed |
| US-20100204203-A1 | Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors | ALCON RESEARCH, LTD. | 2010-08-12 | — | — | US | disclosed |
| EP-2106396-A2 | CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | AstraZeneca AB (SE) | 2009-10-07 | — | — | EP | disclosed |
| US-20090124596-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2009-05-14 | — | — | US | disclosed |
| WO-2008084223-A2 | CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077801-A1 | Chemical Compounds 637 | PDE4A, PDE4B, PDE3B | RAB9A 1736/4885NPC1 2462/4885TNKS 1921/4885 |
| US-20090124596-A1 | Chemical Compounds 637 | PDE4A, PDE4B, PDE3B | RAB9A 1736/4885NPC1 2462/4885TNKS 1921/4885 |
| US-20100204203-A1 | Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors | PDE4A, PDE4B, PDE5A | RAB9A 1730/4885NPC1 3510/4885TNKS 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.